Opus Genetics, Inc. Common Stock
About: Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
Employees: 14
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1,700% more call options, than puts
Call options by funds: $18K | Put options by funds: $1K
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
3% more funds holding
Funds holding: 37 [Q2] → 38 (+1) [Q3]
22% less capital invested
Capital invested by funds: $4.21M [Q2] → $3.28M (-$927K) [Q3]
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Matthew Caufield 24% 1-year accuracy 12 / 50 met price target | 718%upside $8 | Buy Reiterated | 12 Dec 2024 |
Financial journalist opinion
